Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07396766 (BREASTChoice) für Brustkrebs, Brustneoplasmen ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Dissemination of BREASTChoice AIM1-B 20
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07396766 (BREASTChoice) ist eine interventionsstudie zur Untersuchung von Brustkrebs, Brustneoplasmen und hat den Status offene rekrutierung. Die Studie startete am 1. Oktober 2025 und soll 20 Teilnehmer aufnehmen. Durchgeführt von UNC Lineberger Comprehensive Cancer Center ist der Abschluss für 20. Januar 2029 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 9. Februar 2026 aktualisiert.
Kurzbeschreibung
This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants will be observed using the tool on their mobile devices, and their experience will be evaluated using a "think-aloud" method to capture their thoughts and reactions. Interviews will include open-ended questions about the content and format of the decision aid, w...Mehr anzeigen
Ausführliche Beschreibung
This study is part of a larger project that will update and adapt an existing online decision tool called BREASTChoice. The project includes interviews and user testing with breast cancer survivors, interviews with medical experts, and updates to the website design.
Breast reconstruction after a mastectomy is an important part of breast cancer treatment. It can help restore quality of life and body image, which are ...
Mehr anzeigenOffizieller Titel
Dissemination of a Breast Reconstruction Decision Tool Through Social Media and Online Communities- AIM1-B
Erkrankungen
BrustkrebsBrustneoplasmenWeitere Studien-IDs
- BREASTChoice
- 24-1553 AIM1-B
- R01CA276408 (Zuwendung/Vertrag der US-NIH)
NCT-Nummer
Studienbeginn (tatsächlich)
2025-10-01
Zuletzt aktualisiert
2026-02-09
Studienende (vorauss.)
2029-01-20
Geplante Rekrutierung
20
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Offene Rekrutierung
Stichwörter
web-based patient decision aid
BREASTChoice
BREASTChoice
Primäres Ziel
Versorgungsforschung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellBreast cancer survivors Breast cancer survivors. | Basisfragebogen Participants will be screened and share demographic information during screening. If eligible and screened in, the interviewer will send the self-administered pre-survey Decision Quality Index (DQI). Halbstrukturiertes Interview Participants will participate in a semi-structured interview and review of the adapted BREASTChoice tool. Post Survey Participants will take the post-survey to assess breast reconstruction decision quality. |
Hauptergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change in breast reconstruction knowledge | This is knowledge based patient-reported outcome measure uses the Breast Cancer Reconstruction Decision Quality Instrument (DQI). DQ is a 9-item patient-reported measure designed to assess how well patients are informed about breast reconstruction options following breast cancer treatment. The instrument consists of multiple-choice questions with factual, correct answers related to breast reconstruction. Decision quality is quantified as a knowledge score, reflecting the extent to which patients understand key information necessary to make informed reconstruction decisions.
Scores range from 0% to 100%. The total score is calculated by summing the number of correctly answered items and dividing by the total number of questions (9), with higher scores indicating greater knowledge and higher decision quality. | Up to1 week |
Teilnahme-Assistent
Eignungskriterien
Inclusions Criteria To participate in this study, a subject must meet all the eligibility criteria outlined below.
- Age ≥ 18 years at the time of consent
- Able to read and speak English.
- Have had surgery, such as a mastectomy or lumpectomy, to remove some or all of their breast or breasts.
- Breast surgery occurred within the past 8 years.
- Breast surgery was due to a diagnosis of breast cancer, ductal carcinoma in situ, or risk of future breast cancer, by participant report.
- Sex was assigned "Female" at birth
• Individuals with self-reported or observed unstable medical or psychiatric conditions precluding informed consent or participation in the study will be excluded.
UNC Lineberger Comprehensive Cancer CenterNationales Krebsinstitut, USAZentrale Studienkontakte
Kontakt: Victoria Triana, 919-966-4320, [email protected]
Kontakt: Kathryn A Chetwynd, 919-966-4320, [email protected]
1 Studienstandorte in 1 Ländern
North Carolina
The University of North Carolina, Chapel Hill, North Carolina, 27599, United States
Kathryn A Chetwynd, Kontakt, 919-966-4320, [email protected]
Clara Lee, MD, Hauptprüfer
Offene Rekrutierung